Please Wait

Applying Filters...

Medical Breakthroughs in 2024: Alzheimer’s, schizophrenia, COPD, MASH see pathbreaking treatments

Data Compilation
#PharmaFlow

Pipeline Prospector Oct 2024: Lundbeck acquires Longboard for US$ 2.6 bn; molecular glue degrader tech witnesses dealmaking

Stock Recap
#PipelineProspector

Tazobactam Sodium

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

27 API Suppliers, 16 USDMF, 9 JDMF, 4 EU WC, 2 KDMF, 10 NDC API, 6 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

INTERMEDIATES

1 Intermediates Suppliers

1 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

129 FDF Dossiers, 57 FDA Orange Book, 30 Europe, 9 South Africa, 33 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, INJECTABLE;INJECTION - EQ 40MG BASE/ML;EQ 5MG BASE/ML, INJECTABLE;INJECTION - EQ 4GM BASE/100ML;EQ 500MG BASE/100ML, INJECTABLE;INJECTION - EQ 60MG BASE/ML;EQ 7.5MG BASE/ML

RELATED EXCIPIENT COMPANIES

1 SPI Pharma, 1 Faran Shimi Pharmaceutical, 1 Pfanstiehl, 3 Actylis, 1 Pluviaendo, 4 Roquette

EXCIPIENTS BY APPLICATIONS

6 Parenteral, 2 Fillers, Diluents & Binders, 1 API Stability Enhancers, 1 Thickeners and Stabilizers

DIGITAL CONTENT

3 DATA COMPILATION #PharmaFlow, 42 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

28 Finished Drug Prices, 5 Annual Reports

MARKET PLACE

13 APIs, 5 FDF Dossiers

PATENTS & EXCLUSIVITIES

28 US Patents, 3 US Exclusivities

REF. STANDARDS & IMPURITIES

1 USP, 2 Others

$ Xls download

Filters

Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

Last Updated on PharmaCompass	Virtual Booth	Country	Registrant Name	Registration No.	Compound	Registration Date	Manufacturer	Manufacturer's Country	Manufacturer's Address
28/09/2024	Jiangxi Fushine Pharmaceutical Co. Ltd	China	Sangjin Corporation	20190621-210-J-367	Ostrich fermentation	2019-06-21	Jiangxi Fushine Pharmaceutical Co., Ltd.	China	No. 2, Yuli Industrial Zone, Changjiang District, Jingdezhen City, Jiangxi Province, China
28/09/2024	Qilu Tianhe Pharmaceutical Co., Ltd.	China	Korea MSD Co., Ltd.	20200810-210-J-449	Sodium tazobactam	2020-08-10	Shandong Anxin Pharmaceutical Co., Ltd. (formerly Qilu Tianhe Pharmaceutical. Co. Ltd)	China	No. 849, Dongjia Town, Licheng District, 250105 Jinan, Shandong Province, PR of China

Contact us
to update this info

Tazobactam Sodium

Tazobactam Sodium

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

27 API Suppliers

16 USDMF

9 JDMF

4 EU WC

2 KDMF

10 NDC API

6 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

1 Drugs in Development

INTERMEDIATES

1 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

129 FDF Dossiers

57 FDA Orange Book

30 Europe

9 South Africa

33 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;INJECTION - EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

INJECTABLE;INJECTION - EQ 40MG BASE/ML;EQ 5MG BASE/ML

INJECTABLE;INJECTION - EQ 4GM BASE/100ML;EQ 500MG BASE/100ML

INJECTABLE;INJECTION - EQ 60MG BASE/ML;EQ 7.5MG BASE/ML

RELATED EXCIPIENT COMPANIES

1 SPI Pharma

1 Faran Shimi Pharmaceutical

1 Pfanstiehl

3 Actylis

1 Pluviaendo

4 Roquette

EXCIPIENTS BY APPLICATIONS

6 Parenteral

2 Fillers, Diluents & Binders

1 API Stability Enhancers

1 Thickeners and Stabilizers

DIGITAL CONTENT

3 DATA COMPILATION #PharmaFlow

42 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

28 Finished Drug Prices

5 Annual Reports

MARKET PLACE

13 APIs

5 FDF Dossiers

PATENTS & EXCLUSIVITIES

28 US Patents

3 US Exclusivities

REF. STANDARDS & IMPURITIES

1 USP

2 Others

Filters

INJECTABLE;INJECTION - EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

INJECTABLE;INJECTION - EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons